Assembly Biosciences, Inc.

Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesvirus, hepatitis delta virus (HDV) infections, cholestatic liver diseases and hepatitis B virus (HBV). For more information, visit assemblybio.com.

Current securities

1. S-8 filingAug 20, 2026
2. 8-K/A filingAug 14, 2026
3. 10-Q filingAug 13, 2026
4. Completion of Acquisition or Disposition of AssetsAug 13, 2026
5. SCHEDULE 13G/A filingAug 13, 2026